academic article

• Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry..  Pediatric dermatology.  35:303-322. 2018
• Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry..  Pediatric dermatology.  35:303-322. 2018
• Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry..  Pediatric dermatology.  35:303-322. 2018
• Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project..  Drugs in R&D.  17:211-218. 2017
• Life-threatening dermatologic adverse events in oncology..  Anti-cancer drugs.  25:225-234. 2014
• Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's Adverse Event Reporting System and review of case reports in the literature..  Expert opinion on drug safety.  13:15-23. 2014
• Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs..  Expert opinion on drug safety.  12:299-307. 2013